Evaluation of CLINDE as potent translocator protein (18 kDa) SPECT radiotracer reflecting the degree of neuroinflammation in a rat model of microglial activation

[1]  K. Mardon,et al.  Pharmacological evaluation of [123I]-CLINDE: a radioiodinated imidazopyridine-3-acetamide for the study of peripheral benzodiazepine binding sites (PBBS) , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  S. Jan,et al.  In vivo imaging of brain lesions with [11C]CLINME, a new PET radioligand of peripheral benzodiazepine receptors , 2007, Glia.

[3]  Tetsuya Suhara,et al.  A comparison of the high‐affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)‐PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation , 2007, Journal of neurochemistry.

[4]  Philippe Hantraye,et al.  11C-DPA-713: A Novel Peripheral Benzodiazepine Receptor PET Ligand for In Vivo Imaging of Neuroinflammation , 2007, Journal of Nuclear Medicine.

[5]  Ming-Rong Zhang,et al.  N-(5-Fluoro-2-phenoxyphenyl)-N-(2-[(131)I]iodo-5-me thoxybenzyl)acetamide: a potent iodinated radioligand for the peripheral-type benzodiazepine receptor in brain. , 2007, Journal of medicinal chemistry.

[6]  B. Lopresti,et al.  The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: From pathology to imaging , 2006, Progress in Neurobiology.

[7]  D. Nutt,et al.  Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. , 2006, Trends in pharmacological sciences.

[8]  V. Papadopoulos,et al.  Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders , 2006, Neuroscience.

[9]  Ryuji Nakao,et al.  Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  S. Meikle,et al.  Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand. , 2005, Bioorganic & medicinal chemistry.

[11]  Hyun B Choi,et al.  Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum , 2005, Neurobiology of Disease.

[12]  Ronald Boellaard,et al.  Development of a Tracer Kinetic Plasma Input Model for (R)-[11C]PK11195 Brain Studies , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  B. Gulyás,et al.  [11C]Vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies , 2005, Journal of the Neurological Sciences.

[14]  V. Papadopoulos,et al.  Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral-type benzodiazepine receptor. , 2005, Molecular endocrinology.

[15]  F. Mattner,et al.  Evaluation of a radiolabelled peripheral benzodiazepine receptor ligand in the central nervous system inflammation of experimental autoimmune encephalomyelitis: a possible probe for imaging multiple sclerosis , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  F. Fazio,et al.  Evaluation of three quinoline-carboxamide derivatives as potential radioligands for the in vivo pet imaging of neurodegeneration , 2004, Neurochemistry International.

[17]  F. Turkheimer,et al.  Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study , 2004, Neurobiology of Disease.

[18]  L. Raymond,et al.  Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease , 2003, Neurobiology of Aging.

[19]  V. Papadopoulos,et al.  Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis , 2003, Steroids.

[20]  M. Höpfner,et al.  Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cells , 2002 .

[21]  Roger N Gunn,et al.  In-vivo measurement of activated microglia in dementia , 2001, The Lancet.

[22]  A. Lees,et al.  Dopamine neurotransmission, Parkinson’s disease and SPET , 2001, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  R B Banati,et al.  The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. , 2000, Brain : a journal of neurology.

[24]  R B Banati,et al.  Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK11195 , 2000, Neurology.

[25]  Synthesis of substituted [123I]imidazo[1,2-α]pyridines as potential probes for the study of the peripheral benzodiazepine receptors using SPECT , 2000 .

[26]  J. Korf,et al.  In vivo evaluation in mice and metabolism in blood of human volunteers of [123I]iodo-PK11195: a possible single-photon emission tomography tracer for visualization of inflammation , 1999, European Journal of Nuclear Medicine.

[27]  K. Mardon,et al.  Synthesis and evaluation of [I-123]imidazo[1,2-alpha] pyridines as potential probes for the study of the peripheral benzodiazepine receptors using spect. , 1998 .

[28]  G. Reynolds,et al.  Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease , 1998, Neuroscience Letters.

[29]  Alan C. Evans,et al.  PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis , 1997, Journal of neuroscience research.

[30]  D. Guilloteau,et al.  Iodinated PK 11195 as an ex vivo marker of neuronal injury in the lesioned rat brain , 1996, Synapse.

[31]  S. Hume,et al.  Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. , 1994, Nuclear medicine and biology.

[32]  S. Snyder,et al.  Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Richard S. J. Frackowiak,et al.  In Vivo Binding to Peripheral Benzodiazepine Binding Sites in Lesioned Rat Brain: Comparison Between [3H]PK11195 and [18F]PK14105 as Markers for Neuronal Damage , 1990, Journal of neurochemistry.

[34]  C. Carter,et al.  Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage , 1987, Brain Research.

[35]  G. Le Fur,et al.  Photoaffinity labeling of peripheral-type benzodiazepine-binding sites. , 1987, Molecular pharmacology.

[36]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[37]  D. Mason,et al.  Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3. , 1986, Immunology.

[38]  G. Fur,et al.  Labelling of “Peripheral‐Type” Benzodiazepine Binding Sites in the Rat Brain By Using [3H]PK 11195, an Isoquinoline Carboxamide Derivative: Kinetic Studies and Autoradiographic Localization , 1983, Journal of neurochemistry.

[39]  R. Schwarcz,et al.  Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.

[40]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .